Details

<p>List of Contributors, vii</p> <p>Series Foreword, xiii</p> <p>Foreword, xv</p> <p>Preface, xvii</p> <p><b>Part I Principles of Targeted Therapies</b></p> <p>1 Toward Personalized Therapy for Cancer, 3<br /><i>Ashley M. Holder and FundaMeric-Bernstam</i></p> <p>2 Combining Targeted Therapies, 14<br /><i>Jordi Rodon, Analia Azaro, Davis Torrejon, and Razelle Kurzrock</i></p> <p>3 Principles of Targeted Immunotherapy, 27<br /><i>Susanne H. C. Baumeister and Glenn Dranoff</i></p> <p>4 Cancer Stem Cell Principles, 39<br /><i>Allison C. Sharrow, Gabriel Ghiaur, and Richard J. Jones</i></p> <p>5 The Tumor Microenvironment as a Target for Therapeutic Intervention, 47<br /><i>Hua Fang and Yves A. DeClerck</i></p> <p>6 The Role of Angiogenesis in Cancer, 64<br /><i>Morgan Taylor, Robert L. Coleman, and Anil K. Sood</i></p> <p>7 Epigenetics and Epigenetic Therapy of Cancer, 72<br /><i>Omotayo Fasan, Patrick Boland, PatriciaKropf, and Jean-Pierre J. Issa</i></p> <p>8 The Role of microRNAs in Cancer, 80<br /><i>Gianpiero Di Leva and Carlo M. Croce</i></p> <p>9 AcuteMyeloidLeukemia, 89<br /><i>Ofir Wolach and Richard M. Stone</i></p> <p>10 Targeted and Functional Imaging, 101<br /><i>Jian Q. (Michael) Yu, Drew A. Torigian, and Abass Alavi</i></p> <p><b>Part II Targeted Therapy in Hematological Malignancies</b></p> <p>11 Targeted Therapies in Chronic Myeloid Leukemia, 113<br /><i>Elias Jabbour and Jorge Cortes</i></p> <p>12 Targeted Therapy for Acute Lymphoblastic Leukemia, 121<br /><i>Nitin Jain, Susan O’Brien, and Farhad Ravandi-Kashani</i></p> <p>13 Chronic Lymphocytic Leukemia, 130<br /><i>Preetesh Jain and Susan O’Brien</i></p> <p>14 Multiple Myeloma, 145<br /><i>Giada Bianchi and Kenneth C. Anderson</i></p> <p>15 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas, 157<br /><i>Jens G. Lohr and Birgit Knoechel</i></p> <p>16 Targeted Therapy in Myelodysplastic Syndromes, 162<br /><i>Guillermo Montalb´an-Bravo and Guillermo Garc´ya-Manero</i></p> <p>17 Lymphoma and Targeted Therapies, 169<br /><i>Sonali M. Smith and Julie M. Vose</i></p> <p><b>Part III Targeted Therapy in Solid Tumors</b></p> <p>18 Targeted Therapy in Solid Tumors: Brain, 179<br /><i>Shiao-PeiWeathers, Barbara J. O’Brien, John F. de Groot, andW. K. Alfred Yung</i></p> <p>19 Targeted Therapy for Breast Cancer, 190<br /><i>Harold J. Burstein</i></p> <p>20 Targeted Therapy in Solid Tumors: Colorectal Cancer, 193<br /><i>Maen Abdelrahim, Scott Kopetz, and David Menter</i></p> <p>21 Endometrial Cancer, 205<br /><i>Jessica L. Bowser, Russell R. Broaddus, Robert L. Coleman, and Shannon N. Westin</i></p> <p>22 Targeted Therapy in Solid Tumors: Head and Neck, 216<br /><i>Marcus M. Monroe and Jeffrey N. Myers</i></p> <p>23 Targeted Therapy in Solid Tumors: Lung Cancer, 224<br /><i>Saiama N.Waqar, Daniel Morgensztern, and Roy S. Herbst</i></p> <p>24 Targeted Therapy in Melanoma, 231<br /><i>Keith T. Flaherty</i></p> <p>25 Ovarian Cancer, 240<br /><i>Shannon N.Westin, Larissa A. Meyer, and Robert L. Coleman</i></p> <p>26 Molecular Therapeutics: Pancreatic Cancer, 255<br /><i>David Fogelman, Milind Javle, and James Abbruzzese</i></p> <p>27 Targeted Therapies for Pediatric Solid Tumors, 263<br /><i>Jasmine Quynh Dao and Patrick A. Zweidler-McKay</i></p> <p>28 Prostate Cancer, 273<br /><i>William G. Nelson, Michael C. Haffner, and Srinivasan Yegnasubramanian</i></p> <p>29 Renal Cell Carcinoma and Targeted Therapy, 287<br /><i>Benjamin A. Gartrell, Alexander C. Small, William K. Oh, and Matthew D. Galsky</i></p> <p>30 Targeted Therapy in Solid Tumors: Sarcomas, 296<br /><i>Anthony P. Conley, Vinod Ravi, and Shreyaskumar Patel</i></p> <p><b>Part IV Targeted Therapy for Specific Molecular Aberrations</b><br /><br />31 RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities, 305<br /><i>Javier Munoz and Filip Janku</i></p> <p>32 The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies, 315<br /><i>Samuel J. Klempner,Thanh-Trang Vo, Andrea P. Myers, and Lewis C. Cantley</i></p> <p>33 Current Status and Future Direction of PARP Inhibition in Cancer Therapy, 325<br /><i>Saeed Rafii, Stan Kaye and Susana Banerjee</i></p> <p>34 Targeting the c-Met Kinase, 341<br /><i>Chad Tang, M. Angelica Cortez, David Hong, and James W. Welsh</i></p> <p>35 KIT Kinase, 347<br /><i>Scott E. Woodman</i></p> <p>36 TP53, 353<br /><i>Kensuke Kojima and Michael Andreeff</i></p> <p><b>Part V Future Perspectives</b></p> <p>37 Future Perspectives, 363<br /><i>Rabih Said and Apostolia-Maria Tsimberidou</i></p> <p>Index, 371</p>

Apostolia-Maria Tsimberidou, MD PhD<br />Department of Investigational Cancer Therapeutics<br />The University of Texas MD Anderson Cancer Center<br />Houston, TX, USA<br /><br />Razelle Kurzrock<br />Center for Personalized Cancer Therapy, UC San Diego - Moores Cancer Center<br />La Jolla, CA, USA<br /><br />Kenneth C. Anderson MD<br />LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School<br />Boston, MA, USA

<p>In the last decade, emergent technologies have enhanced our understanding of genomic, transcriptional, proteomic, epigenetic, and immune mechanisms in carcinogenesis. This improved understanding has enabled the development of targeted cancer therapies and personalized management, and transformed conventional treatment paradigms. It has provided the framework for the discovery of new targets, for validation of novel agents, for combination therapies predicated upon scientific rationale, and for clinical trials that have already markedly improved the prognosis and outcome of patients with cancer.<br /><br />Over 37 chapters this volume of <i>Translational Oncology</i> series, <i>Targeted Therapy in Translational Cancer Research</i>:<br /><br /></p> <ul> <li>Introduces the cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer</li> <li>Provides a comprehensive overview of recent developments in our understanding of tumor biology and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy</li> <li>Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine</li> <li>Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities</li> </ul> <p><br />We are on the threshold of translating discoveries in cancer biology into unprecedented durable responses and improved clinical outcomes in the majority of patients with cancer. In this unique time in history, the discovery of novel therapeutic approaches targeting the molecular basis of cancer will allow for implementation of precision medicine, with the promise of potentially curative, well tolerated, therapies. Targeted Therapy in Translational Cancer Research was written to increase the awareness and access of basic and clinical researchers, caregivers, and patients alike to cutting-edge “bench to bedside and back” breakthroughs, which have transformed the diagnosis, prognosis, and treatment of cancer.<br /><br />The expert editor team and contributing authors provide an insightful overview to the novel therapeutic approaches targeting the molecular basis of cancer and allowing for the growth of precision medicine. This title is an essential resource for clinical and research oncologists and trainees, pharmacologic research and development professionals, biomedical scientists, and allied oncology professionals.<br /><br />Translational Oncology Series<br />Series Editors<br />ROBERT C. BAST, MD<br />Vice President for Translational Research<br />The University of Texas MD Anderson Cancer Center<br />Houston, TX, USA<br /><br />MAURIE MARKMAN, MD<br />Senior Vice President for Clinical Affairs<br />Cancer Treatment Centers of America<br />Clinical Professor of Medicine<br />Drexel University College of Medicine<br />Philadelphia, PA, USA<br /><br />ERNEST HAWK, MD, MPH<br />Vice President, Division of OVP, Cancer Prevention and Population Sciences<br />The University of Texas MD Anderson Cancer Center<br />Houston, TX, USA<br /><br />Other volumes in the <i>Translational Oncology</i> Series<br />Cancer Gene Therapy by Viral and Non-viral Vectors<br />Edited by Malcolm Brenner and Mien-Chie Hung<br />978-1-118-50162-7</p> <br />

US